Gilead Sciences

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. Read more:

[Gilead Sciences @GileadSciences]

#InTheNews: We're supporting a new clinical trial evaluating an investigational antiviral as a preventative treatment for Ebola Bundibugyo virus disease. The study aims to determine whether treatment after exposure can help prevent Ebola infection.

More: https://t.co/Ke56IcaedB

[Gilead Sciences @GileadSciences]

#InTheNews: Following FDA approval of our treatment for first-line metastatic triple-negative breast cancer (mTNBC), watch coverage highlighting the impact for patients facing one of the most aggressive cancers: https://t.co/q8vjBiCQnf

[STAT Brand Studio @statbrandstudio]

How can innovation in oncology become more meaningful for patients? Dr. Mika Kakefuda Derynck of @GileadSciences and Dr. Gallia Levy of @KitePharma discuss advances in ADCs, CAR T-cell therapies and what it will take to bring these innovations to more people living with cancer.

https://t.co/qoryRJcqCb

[Gilead Sciences @GileadSciences]

#InTheNews: Yesterday, we received FDA approval for our treatment for first-line metastatic triple-negative breast cancer (mTNBC). Read recent coverage highlighting the impact of this approval and our commitment to driving innovation in cancer care: https://t.co/fw394YeLXt

[Gilead Sciences @GileadSciences]

#GileadNews: U.S. FDA approves our treatment for first-line metastatic triple-negative breast cancer, marking a new backbone therapy for people who previously had few options. Read more on this much-needed treatment option for the mTNBC community: https://t.co/BS1yApzJEr

[Gilead Sciences @GileadSciences]

#GileadNews: The European Commission (EC) approves our treatment for first-line metastatic triple-negative breast cancer for patients who are not candidates for PD-(L)1 inhibitors. Read how this marks a much-needed advance for the mTNBC community: https://t.co/ajBxDWnnsZ

[STAT Brand Studio @statbrandstudio]

Cancer care is becoming increasingly personalized.

At STAT@ASCO, @GileadSciences CMO Dietmar Berger discussed how advances in cell therapy, antibody-drug conjugates, and other targeted approaches are helping researchers pursue new ways to treat cancer and improve outcomes for patients.

[Gilead Sciences @GileadSciences]

#GileadNews: The U.S. FDA has accepted our filing for our investigational once-weekly oral option for the prevention of HIV as pre-exposure prophylaxis (PrEP). If approved, this formulation could be the first once-weekly oral PrEP option. Read more: https://t.co/KBBHIAJWcP

[Gilead Sciences @GileadSciences]

#GileadNews: We are donating antiviral medication to the Government of Uganda to support Ebola response efforts.

Additional supplies are being readied to support the regional outbreak response. https://t.co/2mjKsCNGDI

[Gilead Sciences @GileadSciences]

Science has transformed the fight against HIV/AIDS, but there’s more work ahead. Today, the National AIDS Memorial and the Gilead Foundation announced a 3-year, nearly $3M commitment to preserve HIV history and support future community leaders. Learn more: https://t.co/f2rhwqr7RZ

[Gilead Sciences @GileadSciences]

#GileadNews: Today, in collaboration with @Merck, we announced positive topline results from a Phase 3 study evaluating an investigational long-acting oral HIV treatment. Read the full press release here: https://t.co/irnSrVm4GG

[Gilead Sciences @GileadSciences]

#GileadNews: Update on our Phase 3 EVOKE-03 study in first-line PD-L1 ≥50% metastatic non-small cell lung cancer: https://t.co/2oSlzVkhdP

[Gilead Sciences @GileadSciences]

Because of the leadership of the @GovernmentZA and the @GlobalFund, access to long-acting HIV prevention medication is accelerating. This effort underscores the power of global partnership to help drive progress toward ending HIV as a public health threat. https://t.co/sJAvH0HSBp

[Gilead Sciences @GileadSciences]

#GileadNews: Today, we completed our acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. This builds on our long-term strategy to focus on developing transformative medicines that address significant unmet need. https://t.co/8WHIrlid95

[Gilead Sciences @GileadSciences]

We held a high-level meeting with the WHO on the sidelines of the 79th World Health Assembly to announce the five-year renewal of our collaboration to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. ​​ https://t.co/DjAxu5xVdk

[Gilead Sciences @GileadSciences]

#gileadnews: We’ve announced new Phase 3 data looking at ALP normalization in a patient population less extensively studied in primary biliary cholangitis (PBC): https://t.co/8p0koqV0xG

[Gilead Sciences @GileadSciences]

#GileadNews: Today, Gilead presented new data in primary biliary cholangitis (PBC) at #EASL2026, further advancing scientific innovation with the aim to drive positive change for people living with PBC. Read more: https://t.co/6WTW6T4qzW

[Gilead Sciences @GileadSciences]

#GileadNews: The U.S. FDA has granted accelerated approval for our treatment for adults living with chronic hepatitis delta virus (HDV), making it the first and only treatment option in the United States. Read more https://t.co/ALWIhkOxeE

[Gilead Sciences @GileadSciences]

#GileadNews: We received a #CHMP positive opinion for our treatment in first line metastatic triple-negative breast cancer (mTNBC) for patients not candidates for PD-(L)1 inhibitors. https://t.co/wY05AJP7A8

[Gilead Sciences @GileadSciences]

#GileadNews: With @KitePharma, we will be presenting data highlighting advances in our antibody-drug conjugate and cell therapy programs at #ASCO26 and #EHA2026. Read more on our progress in developing treatment options for people living with cancer: https://t.co/b5kQFgPFh8